Number: 201104365 Principal Investigator: Lockhart, A. Craig
Title: An open label, non-randomized Phase I study of regorafenib (BAY 73-4506) to evaluate cardiovascular safety, tolerability, pharmacokinetics, and anti-tumor activity in patients with advanced solid tumors
Phase: I Disease Site: Multiple Sites
Participating Site(s):
Main Campus
Map and Directions
Contact: 800-600-3606 or

The purpose of this study is to find the answers to the following research questions:
1. Are there any side effects to your heart when taking the study drug (BAY 73-4506) that have not yet been seen in other studies using BAY 73-4506?
2. What are the other side effects of BAY 73-4506 when you take it every day for 21 days and then do not take it for 7 days in a 28-day repeating schedule?
3. How much BAY 73-4506 is in the blood and urine at certain time points after you take it?
4. Does BAY 73-4506 cause your tumor to shrink?
More Information: #
Internal Protocol Documents (requires Siteman administrative database password)